BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

673 related articles for article (PubMed ID: 18950515)

  • 21. Clinicopathological characteristics of triple-negative breast cancers.
    Sasaki Y; Tsuda H
    Breast Cancer; 2009; 16(4):254-9. PubMed ID: 19657711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.
    Rhee J; Han SW; Oh DY; Kim JH; Im SA; Han W; Park IA; Noh DY; Bang YJ; Kim TY
    BMC Cancer; 2008 Oct; 8():307. PubMed ID: 18947390
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer.
    Dihge L; Bendahl PO; Grabau D; Isola J; Lövgren K; Rydén L; Fernö M
    Breast Cancer Res Treat; 2008 May; 109(2):255-62. PubMed ID: 17636398
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
    Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
    Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel.
    Torrisi R; Balduzzi A; Ghisini R; Rocca A; Bottiglieri L; Giovanardi F; Veronesi P; Luini A; Orlando L; Viale G; Goldhirsch A; Colleoni M
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):667-72. PubMed ID: 18064460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EGFR gene and protein expression in breast cancers.
    Park K; Han S; Shin E; Kim HJ; Kim JY
    Eur J Surg Oncol; 2007 Oct; 33(8):956-60. PubMed ID: 17374474
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
    Ignatiadis M; Xenidis N; Perraki M; Apostolaki S; Politaki E; Kafousi M; Stathopoulos EN; Stathopoulou A; Lianidou E; Chlouverakis G; Sotiriou C; Georgoulias V; Mavroudis D
    J Clin Oncol; 2007 Nov; 25(33):5194-202. PubMed ID: 17954712
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis.
    Vaziri SA; Krumroy LM; Elson P; Budd GT; Darlington G; Myles J; Tubbs RR; Casey G
    Clin Cancer Res; 2001 Jul; 7(7):1937-45. PubMed ID: 11448907
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is triple negative a prognostic factor in breast cancer?
    Nishimura R; Arima N
    Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EGFR overexpression relates to triple negative profile and poor prognosis in breast cancer patients in Tunisia.
    Kallel I; Khabir A; Boujelbene N; Abdennadher R; Daoud J; Frikha M; Aifa S; Sallemi-Boudawara T; Rebaï A
    J Recept Signal Transduct Res; 2012 Jun; 32(3):142-9. PubMed ID: 22394363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DNA copy number alterations and expression of relevant genes in triple-negative breast cancer.
    Han W; Jung EM; Cho J; Lee JW; Hwang KT; Yang SJ; Kang JJ; Bae JY; Jeon YK; Park IA; Nicolau M; Jeffrey SS; Noh DY
    Genes Chromosomes Cancer; 2008 Jun; 47(6):490-9. PubMed ID: 18314908
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma.
    Thomas DG; Giordano TJ; Sanders D; Biermann S; Sondak VK; Trent JC; Yu D; Pollock RE; Baker L
    Cancer; 2005 Feb; 103(4):830-8. PubMed ID: 15641030
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes.
    Cobleigh MA; Tabesh B; Bitterman P; Baker J; Cronin M; Liu ML; Borchik R; Mosquera JM; Walker MG; Shak S
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8623-31. PubMed ID: 16361546
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer.
    Arnes JB; Brunet JS; Stefansson I; Bégin LR; Wong N; Chappuis PO; Akslen LA; Foulkes WD
    Clin Cancer Res; 2005 Jun; 11(11):4003-11. PubMed ID: 15930334
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression.
    Anders CK; Hsu DS; Broadwater G; Acharya CR; Foekens JA; Zhang Y; Wang Y; Marcom PK; Marks JR; Febbo PG; Nevins JR; Potti A; Blackwell KL
    J Clin Oncol; 2008 Jul; 26(20):3324-30. PubMed ID: 18612148
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1.
    Pintens S; Neven P; Drijkoningen M; Van Belle V; Moerman P; Christiaens MR; Smeets A; Wildiers H; Vanden Bempt I
    J Clin Pathol; 2009 Jul; 62(7):624-8. PubMed ID: 19561231
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TOB1 is regulated by EGF-dependent HER2 and EGFR signaling, is highly phosphorylated, and indicates poor prognosis in node-negative breast cancer.
    Helms MW; Kemming D; Contag CH; Pospisil H; Bartkowiak K; Wang A; Chang SY; Buerger H; Brandt BH
    Cancer Res; 2009 Jun; 69(12):5049-56. PubMed ID: 19491269
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Microcephalin is a new novel prognostic indicator in breast cancer associated with BRCA1 inactivation.
    Richardson J; Shaaban AM; Kamal M; Alisary R; Walker C; Ellis IO; Speirs V; Green AR; Bell SM
    Breast Cancer Res Treat; 2011 Jun; 127(3):639-48. PubMed ID: 20632086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.
    Liu H; Fan Q; Zhang Z; Li X; Yu H; Meng F
    Hum Pathol; 2008 Feb; 39(2):167-74. PubMed ID: 18045647
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epidermal growth factor gene expression in human breast cancer biopsy samples: relationship to estrogen and progesterone receptor gene expression.
    Dotzlaw H; Miller T; Karvelas J; Murphy LC
    Cancer Res; 1990 Jul; 50(14):4204-8. PubMed ID: 2364377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.